Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Abstracts of ECTRIMS (Congress of the European Committee for Treatment and Research in Multiple Sclerosis) 2013. October 2-5, 2013. Copenhagen, Denmark.
Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis.
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.
Mesenchymal stem cells as treatment for MS - progress to date.
Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study.
Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis.
Importance of Rookshana Karma (dehydrating therapy) in the management of transverse myelitis.
High-dose cyclophosphamide in the treatment of multiple sclerosis.
Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study.
FDA approves injectable drug to treat opioid-dependent patients
Tapered withdrawal of phenytoin removes protective effect in EAE without inflammatory rebound and mortality.
JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene.
Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States.
T cell vaccination in multiple sclerosis: results of a preliminary study.
Pathogenic and regulatory roles for B cells in experimental autoimmune encephalomyelitis.
Is multiple sclerosis a proresolution deficiency disorder?
Time to see the light.
Update on biomarkers in neuromyelitis optica.
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process.
Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient.
Studies of EN-1639A (naltrexone): a new narcotic antagonist.
Minocycline in Clinically Isolated Syndromes (CIS) and Early Single Relapse Multiple Sclerosis (MS)
Neuromyelitis optica with very late onset.
Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice.
Inflammatory Response and Chemokine Expression in the White Matter Corpus Callosum and Gray Matter Cortex Region During Cuprizone-Induced Demyelination.

Pages